Reviewer's report

Title: Organ-specific and tumor size-dependent response to sunitinib in clear cell renal cell carcinoma

Version: 2 Date: 23 December 2013

Reviewer: Mayer Fishman

Reviewer's report:

Major essential revisions: None
Minor essential revisions: Since many readers may work off of just the abstract, the conclusions there need to be stated very precisely. Instead of just saying "better", one could specify, higher percentage change.

From:
Patients with CCRCC who have smaller lung metastatic lesions and lower CRP levels may achieve better tumor size reductions with sunitinib therapy than those with extrapulmonary lesions, large lung lesions, and/or higher CRP levels.

to

Patients with CCRCC who have smaller lung metastatic lesions and lower CRP levels may achieve higher percentage change tumor size reductions with sunitinib therapy than those with extrapulmonary lesions, large lung lesions, and/or higher CRP levels.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

No change from prior statement.